Vemlidy and Besivo enters Severance Hospital at the same time

Published: 2017-11-27 13:34:22

Updated: 2017-11-27 13:34:22

‘Vemlidy,’ a Gilead Sciences/Yuhan Corporation’s chronic hepatitis B treatment whose health insurance benefits have been applied from 1 November, and Ildong Pharmaceutical’s ‘Besivo’ entered in Severance Hospital.

Severance Hospital approved Vemlidy and Besivo for a prescription code at its recent drug committee.

The launch of the two new drugs has attracted attention in the chronic hepatitis...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.